GlassScriptPhysician profile
Scott C Rackett
NPI 1235230368
$11,542.67
in general payments reported to CMS, 2019-2025
38 companies · $2,031 in 2025
The $2,031 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,973 · 2020: $350 · 2021: $1,296 · 2022: $1,318 · 2023: $1,884 · 2024: $2,692 · 2025: $2,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,344 · Consulting Fee: $232 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,344.04 |
| Consulting Fee | $232.00 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,275.03 | 2019-2025 | |
| Genzyme Corporation | $1,374.98 | 2019-2025 | |
| Lilly USA, LLC | $759.96 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $665.89 | 2019-2025 | |
| Incyte Corporation | $651.27 | 2022-2025 | Opzelura |
| Ucb, INC. | $607.90 | 2021-2025 | Bimzelx, Cimzia |
| 3m Company | $500.00 | 2019 | |
| Galderma Laboratories, L.P. | $458.04 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Dermavant Sciences, INC. | $448.25 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $411.58 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $334.78 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $328.25 | 2019-2025 | Winlevi, Ilumya |
| Amgen INC. | $285.65 | 2024-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $265.48 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $252.16 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $251.06 | 2019-2025 | Anzupgo, Adbry |
| Arcutis Biotherapeutics, INC. | $240.95 | 2024-2025 | Zoryve |
| Tersera Therapeutics LLC | $232.00 | 2023 | |
| Cepheid | $204.00 | 2021 | |
| Eli Lilly and Company | $175.00 | 2021 | |
| Mimedx Group, INC. | $141.44 | 2024 | |
| Almirall LLC | $135.85 | 2019-2025 | Seysara, Klisyri |
| Epi Health, LLC | $119.46 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $69.32 | 2023-2024 | Sotyktu |
| Botanix Sb INC | $58.31 | 2025 | Sofdra |
| Journey Medical Corporation | $49.12 | 2022-2023 | |
| Aclaris Therapeutics, INC. | $36.89 | 2019 | |
| Biofrontera INC. | $26.42 | 2021 | |
| Verrica Pharmaceuticals INC. | $24.96 | 2025 | Ycanth |
| Dermira, INC. | $24.70 | 2019 | |
| Sandoz INC. | $24.21 | 2019 | |
| Lnhc, INC | $18.70 | 2025 | Zelsuvmi |
| Celgene Corporation | $17.62 | 2019 | |
| Vyne Pharmaceuticals INC. | $17.38 | 2020 | |
| Organon LLC | $16.30 | 2025 | Vtama |
| Dusa Pharmaceuticals, INC. | $15.05 | 2019 | |
| Mission Pharmacal Company | $13.82 | 2019 | |
| Mayne Pharma Commercial LLC | $10.89 | 2024-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Rackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.